The LANCE® Ultra Human BCL-2 Detection Kit is designed for detection and quantitation of human Bcl-2 in buffered solution and cell culture media using a homogeneous TR-FRET (no-wash steps, no separation steps) assay.

• No-wash steps, no separation steps
• TR-FRET technology
• Sensitive detection
• High reproducibility
• Faster time-to-results
• Easy automation
• 96-well, 384-well, and 1536-well formats

LANCE® and LANCE® (Lanthanide chelate excite) Ultra are our TR-FRET (time-resolved fluorescence resonance energy transfer), homogeneous (no wash) technologies. One antibody of interest is labeled with a donor fluorophore (a LANCE Europium chelate) and the second molecule is labeled with an acceptor fluorophore (ULight™ dye). Upon excitation at 320 or 340 nm, energy can be transferred from the donor Europium chelate to the acceptor fluorophore if sufficiently close for FRET (~10 nm). This results in the emission of light at 665 nm.

Bcl-2 (B-cell lymphoma 2) is an oncogenic protein that inhibits apoptosis. It is a protein with a MW of 24-26 kDa, located within the mitochondrial membrane, endoplasmic reticulum and nuclear envelope. Bcl-2 is considered an important antiapoptotic protein and is thus classified as a proto-oncogene. Bcl-2 overexpression has been implicated in a wide variety of malignancies including (but not limited to) breast, prostate, skin, colon and pancreatic cancers as well as neurodegenerative and autoimmune diseases. Related anti-apoptotic proteins include Bcl-xL, Mcl-1 and Bcl-w. Proapoptotic proteins in the Bcl-2 family include Bax, BAD, Bak, Blk and Bid.